Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- NOSCAR(R) Announces NOTES(R) Multicenter Human Trials In The U.S.
- Barrett's Esophagus Patients Have Same Survival Rates As General Population, Says New Mayo Clinic Study
- MorphoSys Receives Regulatory Approval To Start Phase 1b/2a Clinical Trial For MOR103 Program
- Biolaxy Secures IND Approval For Oral Insulin
- Vegetable Juice Aided In Dietary Support For Weight Loss And Lower Blood Pressure
- French Study Is First To Associate Pain Assessment With Improved Outcomes In Mechanically Ventilated ICU Patients
- Popular Stop-Smoking Drugs to Carry Mental Health Risk Warnings
- Drugmaker Recalls Batch of Liquid Acetaminophen
- TCGRx Launches Innovative Tablet-Splitting Device For Pharmacies And Patients
- NeoChord Enrolls First Patient In European Clinical Trial
Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
Posted by: admin in Pharmacy Drugs on March 20th, 2010
BioMedReports.Com, the news portal which covers Wall Street’s biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc. (OTCBB: NVLT), Harry S. Palmin.
It’s become pretty obvious, even to the most casual biotech sector observer, that patients involved in Novelos’ pivotal Phase III trial for lung cancer are living longer than expected.
“These patients with a median survival of eight to ten months unfortunately die pretty quickly,” explains Palmin. “One year survival, which is another way to look at this, is just about 40%.”
But Wall Street has begun to take more interest in the company and the study since over a year and a half after the enrollment target of patients was reached, the number of the expected deaths has not yet occurred.
In the interview, Palmin reveals:
“…Avastin is the only drug in non-small cell lung cancer, first line treatment, that showed a survival advantage. They showed a two month survival advantage, 12.3 months versus 10.3, but the drug has severe toxicities associated with it on top of the chemotherapy toxicities and it’s very expensive. It’s also only available to very few lung cancer patients because the histology it works for is non-squamous.
“The point that I’m trying to make is that given our current statistical projections, we should be on track to achieve or possibly even exceed our possible twelve and a half month median survival target.
“By way of background, we started the pivotal Phase III on lung cancer on the back of three Phase IIs,” explains Palmin. “We saw dramatic survival advantages, better anti-tumor effects and in the United States, we saw doubling response rates and better toleration of chemotherapy.”
The complete interview is available now at BioMedReports.Com.
Biotech investors interested in accessing the news portal’s complete database of clinical trials and upcoming FDA decisions can access that informatio here.
Source
BioMedReports.Com
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.